Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q2

6523.TEDINET S100S7VD
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥166.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥85.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥356.4bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥170.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥89.1bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥4.2bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥2.5bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥10.5bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥8.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax−¥3.0bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥557m2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥179m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.4bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥9.7bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥2.5bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥743m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.2bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥733m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥8.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥570.4bnat 2023-09-30Cons.Assets IFRS
Total assets¥561.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥596.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥423.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥422.7bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥147.0bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥149.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥147.4bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥138.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥148.3bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥61.4bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥73.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥22.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥21.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥17.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥23.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-19.552023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥5.912023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-25.842022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥9.612022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.62022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-19.552023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥5.882023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-25.842022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥9.522022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥65.982022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio25.8%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.6%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.9%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥4.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.7bn
—segment totalrevenue2023-04-01 → 2023-09-30¥165.7bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥165.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥8.9bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥9.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥169.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥169.5bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥20.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 914
ItemContextValueUnit
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration45000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration14743000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration18130000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration442000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-286000000JPY
Other comprehensive income IFRSPrior1YTDDuration16178000000JPY
Other comprehensive income IFRSCurrentYTDDuration17769000000JPY
Comprehensive income IFRSPrior1YTDDuration17619000000JPY
Comprehensive income IFRSCurrentYTDDuration15353000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration17271000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration15275000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration347000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration77000000JPY
Comprehensive income IFRSPrior1YTDDuration17619000000JPY
Comprehensive income IFRSCurrentYTDDuration15353000000JPY
Profit loss IFRSPrior1QuarterDuration8479000000JPY
Profit loss IFRSCurrentQuarterDuration733000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-369000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration206000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration44000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration-1399000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration-11000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration63000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration3250000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration4131000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration135000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration-414000000JPY
Other comprehensive income IFRSPrior1QuarterDuration3050000000JPY
Other comprehensive income IFRSCurrentQuarterDuration2587000000JPY
Comprehensive income IFRSPrior1QuarterDuration11529000000JPY
Comprehensive income IFRSCurrentQuarterDuration3321000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1QuarterDuration11323000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentQuarterDuration3336000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1QuarterDuration206000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentQuarterDuration-15000000JPY
Comprehensive income IFRSPrior1QuarterDuration11529000000JPY
Comprehensive income IFRSCurrentQuarterDuration3321000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember47065000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember44118000000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember28353000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-568000000JPY
Equity IFRSPrior2YearInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Equity IFRSPrior2YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember412000000JPY
Equity IFRSPrior2YearInstant_EffectivePortionOfCashFlowHedgesIFRSMember-92000000JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember1195000000JPY
Profit loss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass